Androgen Deprivation Therapy Market

Androgen Deprivation Therapy Market Analysis

The Androgen Deprivation Therapy Market size is estimated at USD 6.45 billion in 2025, and is expected to reach USD 8.56 billion by 2030, at a CAGR of 5.8% during the forecast period (2025-2030).

The key factors propelling the market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.

The growing burden of prostate cancer is expected to increase demand for effective treatment with androgen deprivation therapy, thereby boosting the market growth. For instance, according to the Canadian Cancer Society Report 2024, prostate cancer is set to account for one in five new cancer cases in Canadian males, with an estimated 27,900 new diagnoses expected in 2024. Thus, the high incidence of prostate cancer is expected to contribute to the segment growth over the forecast period.

Strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players are expected to boost market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare Ltd entered an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, the United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative market growth.

Furthermore, achieving milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) accepted a supplemental New Drug Application (NDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (HSBC). Similarly, in March 2023, the European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Therefore, owing to the factors above, the market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects are expected to hinder the market growth during the study period.

Androgen Deprivation Therapy Market Trends

Antiandrogen Sub-segment Within Drug Class Segment is Expected to Witness a Strong Growth Over the Forecast Period

Anti-androgens are drugs that connect to the androgen receptors, inhibiting the androgens from causing tumor growth. Anti-androgens are also sometimes called androgen receptor antagonists. Antiandrogens drug include flutamide (Eulexin), bicalutamide (Casodex), nilutamide (Nilandron), enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa). Factors such as rising incidences of prostate cancer globally, product approvals, growing geriatric population, increasing research and development activities, and strategies adopted by key market players such as partnerships will effectively contribute to the market growth.

The growing research activities are contributing significantly to the segment's growth. For instance, in September 2023, ESSA Pharma Inc. commenced the Phase 2 segment of its Phase 1/2 trial, focusing on its primary contender, masofaniten (previously labeled EPI-7386). This drug is a pioneering N-terminal domain androgen receptor inhibitor. The study, conducted in collaboration with Astellas Pharma US Inc. and Pfizer, explores the combination of masofaniten with enzalutamide, an antiandrogen, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not been exposed to second-generation antiandrogens.

Additionally, in August 2023, Regeneron Pharmaceuticals Inc. shared promising initial data from its ongoing Phase 1/2 trial, which is investigating REGN5678, an innovative PSMAxCD28 costimulatory bispecific antibody. This trial examines its combination with Regeneron's PD-1 inhibitor, Libtayo (cemiplimab), for treating advanced metastatic castration-resistant prostate cancer (mCRPC). REGN5678 is one of three clinical-stage costimulatory bispecifics in Regeneron's portfolio. These bispecifics are designed to connect T cells to cancer cells, enhancing CD28 signaling to boost anti-tumor activity, particularly when used with Libtayo or a CD3 bispecific.

Thus, due to the factors mentioned above such as increasing research and development activities by pharmaceutical companies, the studied segment is expected to contribute to the significant growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The primary driving factors for the growth of the North American androgen deprivation therapy (ADT) market are the rising prevalence of prostate cancer, the growing geriatric population, product launches, and several initiatives and investments made by key market players.

The United States within North America is expected to hold a significant share of the studied market during the study period. Prostate cancer is the most common cancer in American men. The American Cancer Society estimated that in the United States in 2024, about 299,010 new cases of prostate cancer are expected to be reported. Thus, the country's huge burden of prostate cancer is expected to increase the demand for its therapeutics. It can suppress the formation of testosterone, contributing to market growth.

The above source also suggests prostate cancer is more likely to develop in older men. About six cases in 10 are diagnosed in men 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. Thereby, the growing elderly population in the region will also increase the incidence rate of prostate cancer, propelling the market.

The rising research and development studies proving the efficacies of androgen receptor inhibitors in treating pancreatic cancer will contribute to market growth. For instance, in May 2024, Johnson & Johnson released findings from the Phase 2 Apa-RP study, an open-label, single-arm trial. The study assessed the adjuvant treatment of ERLEADA (apalutamide) alongside androgen deprivation therapy (ADT) in patients with high-risk localized prostate cancer (HRLPC) post-radical prostatectomy (RP). Notably, all patients under this regimen maintained a 100% biochemical recurrence (BCR)-free status at the 24-month mark post-RP. Such technological improvement in treatment procedures is expected to drive market growth.

Therefore, the market studied is expected to lead to lucrative growth in North America due to the growing burden of prostate cancer and increasing research and development activities by the market players.

Androgen Deprivation Therapy Industry Overview

The androgen deprivation therapy market is moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by the key players will boost the market. The major players in the market studied are Johnson & Johnson, AstraZeneca, Bayer AG, Astellas Pharma, and Tolmar Pharmaceuticals Inc.

Androgen Deprivation Therapy Market Leaders

Androgen Deprivation Therapy Market News

• July 2024: Ubix Therapeutics Inc. entered an exclusive licensing agreement with Yuhan Corporation. The deal focuses on developing and commercializing UBX-103, a preclinical androgen receptor (AR) degrader program. Yuhan will have exclusive, worldwide rights for the preclinical and clinical development and commercialization of UBX-103. Ubix will receive an upfront payment of more than USD 3.6 million (approximately KRW 5 billion).
• March 2023: OliX Pharmaceuticals Inc. announced that it received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021. It is a treatment for androgenic alopecia, also known as male-pattern baldness. OLX72021 suppresses the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor.